- Home
- GLMD vs ONVO Comparison
GLMD vs ONVO Comparison
Compare GLMD & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- ONVO
- Stock Information
- Founded
- GLMD 2000
- ONVO 2007
- Country
- GLMD Israel
- ONVO United States
- Employees
- GLMD N/A
- ONVO N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLMD Health Care
- ONVO Health Care
- Exchange
- GLMD Nasdaq
- ONVO Nasdaq
- Market Cap
- GLMD 3.0M
- ONVO 3.0M
- IPO Year
- GLMD 2014
- ONVO N/A
- Fundamental
- Price
- GLMD $1.57
- ONVO $1.87
- Analyst Decision
- GLMD Hold
- ONVO
- Analyst Count
- GLMD 1
- ONVO 0
- Target Price
- GLMD N/A
- ONVO N/A
- AVG Volume (30 Days)
- GLMD 105.5K
- ONVO 347.1K
- Earning Date
- GLMD 05-29-2025
- ONVO 05-30-2025
- Dividend Yield
- GLMD N/A
- ONVO N/A
- EPS Growth
- GLMD N/A
- ONVO N/A
- EPS
- GLMD N/A
- ONVO N/A
- Revenue
- GLMD N/A
- ONVO $122,000.00
- Revenue This Year
- GLMD N/A
- ONVO $59.08
- Revenue Next Year
- GLMD N/A
- ONVO $18.24
- P/E Ratio
- GLMD N/A
- ONVO N/A
- Revenue Growth
- GLMD N/A
- ONVO N/A
- 52 Week Low
- GLMD $1.21
- ONVO $1.56
- 52 Week High
- GLMD $23.80
- ONVO $21.96
- Technical
- Relative Strength Index (RSI)
- GLMD 48.70
- ONVO 37.84
- Support Level
- GLMD $1.30
- ONVO $1.56
- Resistance Level
- GLMD $1.67
- ONVO $1.78
- Average True Range (ATR)
- GLMD 0.14
- ONVO 0.24
- MACD
- GLMD 0.06
- ONVO 0.13
- Stochastic Oscillator
- GLMD 78.77
- ONVO 43.06
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.